Komfymed

Komfymed is a biopharmaceutical company focused on the development of high-end inhaled medications for respiratory and pulmonary vascular diseases. Utilizing its proprietary dry powder inhalation (DPI) and soft mist inhalation technology platforms, the company develops formulations designed for superior lung deposition and stability. Komfymed's lead programs target major indications such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary arterial hypertension (PAH). The company is headquartered in Suzhou, China, and aims to provide more effective and convenient treatment options for patients globally. Their approach combines advanced particle engineering with innovative device design to optimize drug delivery to the deep lungs.